1.Comparative study on irritable bowel syndrome treated with acupuncture and western medicine.
Zhi-Min SHI ; Ye-Shan ZHU ; Qing-Xian WANG ; Miao-Na LEI
Chinese Acupuncture & Moxibustion 2011;31(7):607-609
OBJECTIVETo compare the differences in the therapeutic effect on irritable bowel syndrome (IBS) between acupuncture at Tianshu (ST 25) and Dachangshu (BL 25) and western medication with Trimebutine Maleate.
METHODSForty cases were divided randomly into an acupuncture group and a western medication group, 20 cases in each one. In acupuncture group, acupuncture was applied to Tianshu (ST 25) and Dachangshu (BL 25). Ziwu Daojiu needling technique was adopted, once daily. In western medication group, Trimebutine Maleate capsule was administered, 2 capsules in each time, 3 times per day. The assessment on the therapeutic effect was performed in 4 weeks of treatment in two groups.
RESULTSAs compared with those before treatment, the time of abdominal pain, the frequency of abdominal pain, the morbidity of abnormal stool appearance, the morbidity of defecation abnormality, the morbidity of mucus stool and the score of bloating or abdominal pain on bowel movement were all reduced after treatment in two groups (all P < 0.01). The results in acupuncture group were much more significant than those in western medication group (the total score: 16.70 +/- 2.40 vs 15.70 +/- 3.01, P < 0.01). The total effective rate in acupuncture group was 95.0% (19/20), which was superior to that of 70.0% (14/20) in western medication group (P < 0.05).
CONCLUSIONAcupuncture at Tianshu (ST 25) and Dachangshu (BL 25) may remarkably relieve the clinical symptoms of IBS and its efficacy is superior to that of oral medication with Trimebutine Maleate.
Acupuncture Therapy ; Adolescent ; Adult ; Aged ; Child ; Female ; Humans ; Irritable Bowel Syndrome ; drug therapy ; therapy ; Male ; Middle Aged ; Trimebutine ; therapeutic use ; Young Adult
2.Efficacy of Fenoverine and Trimebutine in the Management of Irritable Bowel Syndrome: Multicenter Randomized Double-blind Non-inferiority Clinical Study.
Seong Hee KANG ; Yoon Tae JEEN ; Ja Seol KOO ; Yang Seo KOO ; Kyoung Oh KIM ; You Sun KIM ; Seung Yeong KIM ; Jeong Seop MOON ; Jong Jae PARK ; Il Hyun BAEK ; Sung Chul PARK ; Sung Joon LEE ; Jong Hun LEE ; Rok Seon CHOUNG ; Suck Chei CHOI
The Korean Journal of Gastroenterology 2013;62(5):278-287
BACKGROUND/AIMS: Antispasmodic agents have been used in the management of irritable bowel syndrome. However, systematic reviews have come to different conclusions about the efficacy in irritable bowel syndrome. Fenoverine acts as a synchronizer of smooth muscle in modulating the intracellular influx of calcium. We compared fenoverine with trimebutine for the treatment of patients with IBS. METHODS: A multicenter, randomized, double-blind, non-inferiority clinical study was conducted to compared fenoverine with trimebutine. Subjects were randomized to receive either fenoverine (100 mg three times a day) or trimebutine (150 mg three times a day) for 8 weeks. A total of 197 patients were analyzed by the intention-to-treat approach. The primary endpoint was the proportion of patients who had 30% reduction in abdominal pain or discomfort measured by bowel symptom scale (BSS) score at week 8 compared to the baseline. The secondary endpoints were changes of abdominal bloating, diarrhea, constipation, overall and total scores of BSS, and overall satisfaction. RESULTS: At week 8, fenoverine was shown to be non-inferior to trimebutine (treatment difference, 1.76%; 90% CI, -10.30-13.82; p=0.81); 69.23% (54 of 78 patients) of patients taking fenoverine and 67.47% (56 of 83 patients) of patients taking trimebutine showed 30% reduction in abdominal pain or discomfort compared to the baseline. There results of the secondary endpoints were also comparable between the fenoverine group and the trimebutine group. CONCLUSIONS: Fenoverine is non-inferior to trimebutine for treating IBS in terms of both efficacy and tolerability.
Abdominal Pain/etiology
;
Adult
;
Constipation/etiology
;
Diarrhea/etiology
;
Double-Blind Method
;
Drug Administration Schedule
;
Female
;
Humans
;
Irritable Bowel Syndrome/complications/*drug therapy
;
Male
;
Middle Aged
;
Parasympatholytics/*therapeutic use
;
Phenothiazines/*therapeutic use
;
Severity of Illness Index
;
Treatment Outcome
;
Trimebutine/*therapeutic use